Innate Pharma (Innate Pharma) Debt-to-EBITDA : -2.44 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Innate Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $9.75 Mil. Innate Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $33.76 Mil. Innate Pharma's annualized EBITDA for the quarter that ended in Dec. 2023 was $-17.81 Mil. Innate Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -2.44.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Innate Pharma's Debt-to-EBITDA or its related term are showing as below:

IPHA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -21.69 Med: -0.19 Max: 0.76
Current: -21.69

During the past 13 years, the highest Debt-to-EBITDA Ratio of Innate Pharma was 0.76. The lowest was -21.69. And the median was -0.19.

IPHA's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs IPHA: -21.69

Innate Pharma Debt-to-EBITDA Historical Data

The historical data trend for Innate Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Debt-to-EBITDA Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

0.76

0.34

-1.09

-3.44

-21.70

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.87	1.49	-0.79	3.21	-2.44

Competitive Comparison of Innate Pharma's Debt-to-EBITDA

For the Biotechnology subindustry, Innate Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Debt-to-EBITDA falls into.

Innate Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Innate Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(9.745	+	33.759)	/	-2.005
	=	-21.70

Innate Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(9.745	+	33.759)	/	-17.814
	=	-2.44

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Innate Pharma (NAS:IPHA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Innate Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (Innate Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

IPHYF:USA 0EVI:UK IPH:France IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.